Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated SARS-CoV-2 S protein RBD (K417T, E484K, N501Y), His,Avitag™, 25µg  

Recombinant Biotinylated SARS-CoV-2 S protein RBD (K417T, E484K, N501Y), His,Avitag™, 25µg

Recombinant Biotinylated SARS-CoV-2 S protein RBD (K417T, E484K, N501Y), (P.1, 20J/501Y.V3), AA Arg 319 - Lys 537, expressed from human 293 cells (HEK293), His,Avitag™

Synonyms: Recombinant, Spike, S protein RBD, Spike glycoprotein Receptor-binding domain, S glycoprotein RBD, Spike protein RBD

More details

SPD-C82E7-25

Availability: within 7 days

494,00 €

Background
It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Source
Recombinant Biotinylated SARS-CoV-2 S protein RBD (K417T, E484K, N501Y), His,Avitag (SPD-C82E7) is expressed from human 293 cells (HEK293). It contains AA Arg 319 - Lys 537 (Accession # QHD43416.1(K417T, E484K, N501Y)). K417T/ E484K/ N501Y mutations were identified in the SARS-CoV-2 Gamma variant (Pango lineage: P.1; other names: 20J/501Y.V3).
Predicted N-terminus: Arg 319

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag.
The protein has a calculated MW of 28.2 kDa. The protein migrates as 33-40 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio

Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Bioactivity
Please refer to product data sheet.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Inactivation mechanism of cold plasma combined with 222 nm ultraviolet for spike protein and its application in disinfecting of SARS-CoV-2"
Sheng, Wang, Zhao et al
J Hazard Mater (2024) 465, 133458
(2) "TXM peptides inhibit SARS-CoV-2 infection, syncytia formation, and lower inflammatory consequences"
Govednik, Lainšček, Kuhar et al
Antiviral Res (2024)
(3) "Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2"
Dulin, Barre, Xu et al
J Virol (2024)
Showing 1-3 of 4323 papers.

The following products could also be interesting for you: